New T-cell therapy shows promise in treating hard-to-treat eye cancer

(MedPage Today) – Berlin – A single infusion of the PRAME-directed T-cell receptor antagonist anzotresgin otoleucel (anzu-cel) demonstrated encouraging antitumor activity in patients with previously treated advanced or metastatic disease.